Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis

Table 4 Predictors for non-persistence to bisphosphonates in patients with rheumatoid arthritis

Variables	Univariable		^aMultivariable
Variables	HR (95% CI)	p value	HR (95% CI)	p value
Dosing frequency weekly vs. monthly BPs	2.16 (1.67–2.79)	<0.001	2.19 (1.69–2.83)	<0.001
Seropositive RA	0.69 (0.51–0.95)	0.023	0.68 (0.49–0.92)	0.014
Disease duration ≥ 24 months	0.69 (0.54–0.88)	0.003	-	-
Previous compression fracture	1.44 (0.98–2.12)	0.062	-	-
Reimbursement for BPs	0.85 (0.66–1.08)	0.192	-	-
Age, years	0.99 (0.98–1.01)	0.604	-	-
Glucocorticoids use	1.06 (0.72–1.55)	0.763
Calcium /vitamin D supplement	1.08 (0.78–1.5)	0.622
Baseline DEXA	0.84 (0.57–1.24)	0.373
DAS28-ESR	1.02 (0.95–1.09)	0.586

BPs Bisphosphonates, RA Rheumatoid arthritis, DEXA dual energy X-ray absorptiometry, DAS28-ESR disease activity score assessed using the 28-joint count for swelling and tenderness- erythrocyte sedimentation rate
^aEstimated using multivariable backward logistic regression models including dosing frequency of BPs, seropositive RA, disease duration > 24 months, previous compression fracture, reimbursement for BPs and age

ISSN: 1471-2474